Back to search
FDAFDA · Food and drugs·Recall number D-0238-2019

Testosterone 200 mg/Anastrozole 20 mg pellet, 1 count (NDC 69761-222-01), 6 count (NDC 69761-222-06), 12 count (NDC 69761-222-12), and 30 count (NDC 69761-222-30) vials, Rx Only, Qualgen, Edmond, OK 73013

Published November 14, 2018 · Recall initiated: October 17, 2018

Summary

FDA records drug Class II recall D-0238-2019, published November 14, 2018 and initiated October 17, 2018. Recalling firm: Qualgen, LLC; Status: Terminated; Lot: Lot: C254 BUD: 12/13/2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Qualgen, LLC
Distributor
Nationwide.
Lot
Lot: C254 BUD: 12/13/2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Testosterone 200 mg/Anastrozole 20 mg pellet, 1 count (NDC 69761-222-01), 6 count (NDC 69761-222-06), 12 count (NDC 69761-222-12), and 30 count (NDC 69761-222-30) vials, Rx Only, Qualgen, Edmond, OK 73013 recalled?

Yes. FDA published recall D-0238-2019 on November 14, 2018. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter